Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study
It contains the same active ingredient Semaglutide compounded in licensed U.S
In the STEP 3 randomised trial, once weekly semaglutide 2.4 mg used in obese adults without diabetes was associated with 4.9% incidence of gallbladder related disorders (mainly cholelithiasis) compared with 1.5% in the placebo group (1)
Broader clinical trial data suggests that approximately 10% of patients across all indications and doses may discontinue semaglutide due to GI complaints, which is comparable to or slightly higher than other GLP-1 receptor agonists
On the other hand, the ideal candidate for a GLP-1 medication like the ones we prescribe at TrimrX often presents with metabolic issues alongside their weight concerns
There has also been concern about the impact on metabolism and overall health after prolonged use
US$ 21.62
US$ 23.22
US$ 22.01
)
US$ 26.58
